Compare MXC & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | CTXR |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 18.7M |
| IPO Year | 1995 | 2010 |
| Metric | MXC | CTXR |
|---|---|---|
| Price | $10.32 | $0.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 25.3K | ★ 910.8K |
| Earning Date | 02-10-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | $41.46 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $7.16 | $0.47 |
| 52 Week High | $16.48 | $2.19 |
| Indicator | MXC | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 49.26 |
| Support Level | $9.89 | $0.56 |
| Resistance Level | $10.45 | $0.61 |
| Average True Range (ATR) | 0.65 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 82.32 | 42.22 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.